Potency matters: Thresholds govern endocrine activity

Regulatory Toxicology and Pharmacology

Volumn 67, Issue 1, 2013, Pages 83-88

  Borgert, Christopher J ^a   Baker, Stephen P ^b   Matthews, John C ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Endocrine active substances; Endocrine disruption; Endocrine pharmacology; Hormone affinity; Hormone efficacy; Hormone potency; Potency threshold

Indexed keywords

ENDOCRINE DISRUPTOR; ESTROGEN;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; CONCENTRATION RESPONSE; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; ESTROGEN ACTIVITY; HEALTH HAZARD; HORMONAL CARCINOGENESIS; HORMONE BINDING; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSE; HUMAN; LIGAND BINDING; MASS ACTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ENDOCRINE ACTIVE SUBSTANCES; ENDOCRINE DISRUPTION; ENDOCRINE PHARMACOLOGY; HORMONE AFFINITY; HORMONE EFFICACY; HORMONE POTENCY; POTENCY THRESHOLD;

ANIMALS; ENDOCRINE DISRUPTORS; ENDOCRINE SYSTEM; EUROPEAN UNION; HORMONES; HUMANS;

EID: 84883445083     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.06.007     Document Type: Article

References (42)

1. Björnström L., Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 2005, 19:833-842.
2. Boobis A.R., Daston G.P., Preston R.J., Olin S.S. Application of key events analysis to chemical carcinogens and noncarcinogens. Crit. Rev. Food Sci. Nutr. 2009, 49:690-707.
3. Borgert C.J., LaKind J.S., Witorsch R.J. A critical review of methods for comparing estrogenic activity of endogenous and exogenous chemicals in human milk and infant formula. Environ. Health Perspect. 2003, 111:1020-1036.
4. Borgert C.J., Sargent E.V., Casella G., Dietrich D.R., McCarty L.S., Golden R.J. The human relevant potency threshold: reducing uncertainty by human calibration of cumulative risk assessments. Regul. Toxicol. Pharmacol. 2012, 62:313-328.
5. Brooks J.D., Ward W.E., Lewis J.E., et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. Am. J. Clin. Nutr. 2004, 79:318-325.
6. Caldwell D.J., Mastrocco F., Anderson P.D., Länge R., Sumpter J.P. Predicted-no-effect concentrations for the steroid estrogens estrone, 17β-estradiol, estriol, and 17α- ethinylestradiol. Environ. Toxicol. Chem. 2012, 31:1396-1406.
7. Chedrese P.J. Introduction to the molecular organization of the endocrine/reproductive system. Reproductive Endocrinology, A Molecular Approach 2009, Springer, New York, (Chapter 1). P.J. Chedrese (Ed.).
8. Chedrese P.J., Celuch S.M. Extracellular signaling receptors. Reproductive Endocrinology, A Molecular Approach 2009, Springer, New York, (Chapter 2). P.J. Chedrese (Ed.).
9. Chen Z., Katzenellenbogen B.S., Katzenellenbogen J.A., Zhao H. Directed evolution of human estrogen receptor variants with significantly enhanced androgen specificity and affinity. J. Biol. Chem. 2004, 279:33855-33864.
10. Clarke W.P., Bond R.A. The elusive nature of intrinsic efficacy. Trends Pharmacol. Sci. 1998, 19:270-276.
11. Cleve A., Fritzemeier K.H., Haendler B., et al. Pharmacology and clinical use of sex steroid hormone receptor modulators. Handb. Exp. Pharmacol. 2012, 214:543-587.
12. Colli M.C., Bracht A., Soares A.A., et al. Evaluation of the efficacy of flaxseed meal and flaxseed extract in reducing menopausal symptoms. J. Med. Food 2012, 15:840-845.
13. Dietrich D.R. Courage for simplification and imperfection in the 21st century assessment of "Endocrine disruption". ALTEX 2010, 27:264-278.
14. Eden J.A. Human breast cancer stem cells and sex hormones-a narrative review. Menopause 2010, 17:801-810.
15. Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000, 356:1255-1259.
16. EFSA (European Food Safety Authority), Scientific opinion on the hazard assessment of endocrine disruptors: scientific criteria for identification of endocrine disruptors and appropriateness of existing test methods for assessing effects mediated by the substances on human health and environment, 2013.
17. Falkenstein E., Tillmann H.C., Christ M., Feuring M., Wehling M. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol. Rev. 2000, 52:513-556.
18. Golden R.J., Noller K.L., Titus-Ernstoff L., et al. Environmental endocrine modulators and human health: an assessment of the biological evidence. Crit. Rev. Toxicol. 1998, 28:109-227.
19. Grannar D.K. Hormonal action. Principles and Practice of Endocrinology and Metabolism 1993, J.B. Lippincott Company, Philadelphia, (Chapter 3). second ed. K.L. Becker (Ed.).
20. Gronemeyer H., Gustafsson J.A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 2004, 3:950-964.
21. Hass U., Christiansen S., Axelstad M., Sørensen K.D., Boberg J. Input for the REACH-Review in 2013 on Endocrine Disruptors 2013, Danish Center on Endocrine Disrupters, DTU Food National Food Institute.
22. KemI (Swedish Chemicals Agency), Is it possible to determine thresholds for the effects of endocrine disruptors? A summary of scientific argumentation from 15 relevant publications on endocrine disruption. 2013a. http://www.kemi.se/Documents/Publikationer/Trycksaker/PM/PM2-13.pdf.
23. KemI (Swedish Chemicals Agency), The Swedish Chemicals Agency's position on the possibility to determine threshold levels for endocrine disrupters. Memo, 2013. Reference 4.4b-H13-00416. 2013b.
24. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol. Sci. 2004, 25:186-192.
25. Kenakin T. Ligand-receptor binding and tissue response. Pharmacology: Principles and Practice 2009, Academic Press, Amsterdam, (Chapter 4).
26. Kuiper G.G., Carlsson B., Grandien K., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
27. Li J.J., Nandi S., Li S.A. Hormones and carcinogenesis: laboratory studies. Principles and Practice of Endocrinology and Metabolism 1993, J.B. Lippincott Company, Philadelphia, (Chapter 215). second ed. K.L. Becker (Ed.).
28. Liu J., Burdette J.E., Sun Y., et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus-castus L. (chaste-berry). Phytomedicine 2004, 11:18-23.
29. Marty M.S., Carney E.W., Rowlands J.C. Endocrine disruption: historical perspectives and its impact on the future of toxicology testing. Toxicol. Sci. 2011, 120(Suppl. 1):S93-S108.
30. Matthews J.C. Fundamentals of Receptor, Enzyme, and Transport Kinetics 1993, CRC Press, Boca Raton, FL.
31. Menendez J.A., Colomer R., Lupu R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma- linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. Int. J. Cancer 2004, 109:949-954.
32. Lehninger Principles of Biochemistry 2008, W.H. Freeman & Co., NY, p.1138. fifth ed. D.L. Nelson, M.M. Cox (Eds.).
33. Piersma A.H., Hernandez L.G., Van Benthem J., et al. Reproductive toxicants have a threshold of adversity. Crit. Rev. Toxicol. 2011, 41:545-554.
34. Prahalada S., Hendrickx A.G. Embryotoxicity of Norlestrin, a combined synthetic oral contraceptive, in rhesus macaques (Macaca mulatta). Teratology 1983, 27:215-222.
35. Rose D.P., Connolly J.M. Stimulation of growth of human breast cancer cell lines in culture by linoleic acid. Biochem. Biophys. Res. Commun. 1989, 164:277-283.
36. Sacco S.M., Jiang J.M., Thompson L.U., Ward W.E. Flaxseed does not enhance the estrogenic effect of low-dose estrogen therapy on markers of uterine health in ovariectomized rats. J. Med. Food 2012, 15:846-850.
37. Shaak T.L., Wijesinghe D.S., Chalfant C.E., Diegelmann R.F., Ward K.R., Loria R.M. Structural stereochemistry of androstene hormones determines interactions with human androgen, estrogen, and glucocorticoid receptors. Int. J. Med. Chem. 2013, 2013:1-8.
38. Simons S.S. How much is enough? Modulation of dose-response curve for steroid receptor- regulated gene expression by changing concentrations of transcription factor. Curr. Top. Med. Chem. 2006, 6:271-285.
39. Simons S.S. What goes on behind closed doors: physiological versus pharmacological steroid hormone actions. Bioessays 2008, 30:744-756.
40. UNEP and WHO, 2013. State of the Science of Endocrine Disrupting Chemicals - 2012.
41. Witorsch R.J. Low-dose in utero effects of xenoestrogens in mice and their relevance to humans: an analytical review of the literature. Food Chem. Toxicol. 2002, 40:905-912.
42. Wu F., Khan S., Wu Q., Barhoumi R., Burghardt R., Safe S. Ligand structure-dependent activation of estrogen receptor alpha/Sp by estrogens and xenoestrogens. J. Steroid. Biochem. Mol. Biol. 2008, 110:104-115.